Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 1989 results for nice guidelines

  1. The Epidrum for aiding access to the epidural space (MIB23)

    NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space

    Medtech innovation briefing
    Published
    2 March 2015

  2. Episcissors-60 show promise for mediolateral episiotomy. But there is currently not enough evidence to support the case for routine adoption in the NHS. Research is recommended to address uncertainties about the efficacy and safety of using Episcissors-60. This research should: - determine if using Episcissors-60 in addition to other care bundle measures is more effective in achieving an optimal episiotomy angle and in preventing episiotomy-related obstetric anal sphincter injuries (OASI) than standard episiotomy scissors - include patient-reported outcome measures - address potential equality considerations by ensuring patients at greatest risk of OASI are recruited - determine the relative cost of using Episcissors-60 compared with standard episiotomy scissors.

    at an optimal angle (45 to 60 degrees to the midline, according to NICE's guideline on intrapartum care) during delivery....

    Research recommendation
    Published
    17 March 2020

  3. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

    News
    Last updated
    8 December 2025

  4. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    15 November 2017
    View recommendations

    Sections for TA488

  5. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA345

  6. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  7. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  8. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  9. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development Reference number: GID-TA11228 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA862

  11. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    cancer. But you do not have to take it: there are pros and cons. The medicine NICE recommends for most women who have been through the...

  12. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

  13. Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

    Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.

    Technology appraisal guidance
    Published
    16 October 2024
    View recommendations

    Sections for TA1011

  14. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  15. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA926